Dr Reddy’s To Sell Its Anti-Cancer Agent To Citius Pharma
Citius Pharmaceuticals Inc (NASDAQ:CTXR) has agreed to acquire anti-cancer agent E7777 from Dr. Reddy’s Laboratories Ltd (NYSE:RDY). E7777 is an engineered IL-2-diphtheria toxin…
Citius Pharmaceuticals Q3 EPS $(0.05) Up From $(0.11) YoY
Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.05) per share. This is a 54.55 percent increase over losses of $(0.11) per share from the same period last year.
Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs
Image by falco from Pixabay
What happens when the one product keeping you alive becomes infected?
56 Biggest Movers From Friday
Gainers
Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
T.A.T. Technologies Ltd. (NASDAQ: TATT) shares rose 53.4% to $9.09 in pre-market trading after the company announced a new MRO partnership with Honeywell.
58 Biggest Movers From Yesterday
Gainers
The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.